Search clinical trials for: the First Line Therapy

Total 225530 results

The First Hospital of Jilin University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Diffuse Large B-cell Lymphoma

China
IDEAYA Biosciences

Recruiting

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States, Canada, Israel, Spain, Australia, Germany, France, Italy, United Kingdom, Netherlands, Belgium, Poland, Switzerland
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Fudan University

Recruiting

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer (BCTOP-L-M01)

Breast Cancer | Advanced Breast Cancer

China
Sun Yat-sen University

Recruiting

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Pleural Mesothelioma

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
University of Aarhus
Odense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaborators

Recruiting

First-line Treatment for Femoroacetabular Impingement Syndrome (BetterHip)

Femoroacetabular Impingement Syndrome

Denmark, Australia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Professor Francois Venter
Merck Sharp & Dohme LLC; Africa Health Research Institute

Recruiting

A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy (Opti-DOR)

HIV-1-infection

South Africa
Biotheus Inc.

Recruiting

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

TNBC

China
Biotheus Inc.

Recruiting

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

MPM

China
IconOVir Bio

Recruiting

Safety and Tolerability of Intravenous Administration of ICVB-1042

Patients With Advanced Solid Tumors

United States
Hirva Mamdani
AstraZeneca; Barbara Ann Karmanos Cancer Institute

Recruiting

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

Small Cell Lung Cancer | SCLC | Extensive Stage Small Cell Lung Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

Breast Cancer

United States, Puerto Rico
Biotheus Inc.

Recruiting

PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Xinqiao Hospital of Chongqing

Recruiting

A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies

Artificial Intelligence | Malignant Tumor | Immunotherapy

China
Australasian Gastro-Intestinal Trials Group
Cancer Council Victoria; Walter and Eliza Hall Institute of Medical Research

Recruiting

RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (RESOLUTE)

Colorectal Cancer | Oligometastatic Disease

Australia
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Third Affiliated Hospital... and other collaborators

Recruiting

Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM) (DEFORM)

Functional Mitral Regurgitation

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Multiple Myeloma

China
Fujian Cancer Hospital

Recruiting

Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Colorectal Cancer

China
RenJi Hospital
Shanghai Zhongshan Hospital

Not yet recruiting

Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study

First-line Treatment of Non-clear Renal Cell Carcinoma
Pulnovo Medical (Wuxi) Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Recruiting

A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure (PADN-HF-PH)

Cardiovascular Diseases | Vascular Diseases | Heart Failure | Hypertension | Pulmonary Hypertension | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure With Mid Range Ejection Fraction

China
Bristol-Myers Squibb

Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada, Taiwan, United States, Australia, Denmark, China, Korea, Republic of, Israel, Spain, France, Germany, Czechia, Austria, Japan, Sweden, United Kingdom, Greece, Italy, Finland, Argentina, Belgium, Brazil, Colombia, Hong Kong, India, Mexic... and more
Fujian Cancer Hospital

Recruiting

HRQOL in Locally Advanced Thyroid Carcinoma (LATCQOL)

Thyroid Cancer | Health Related Quality of Life | Tyrosine Kinase Inhibitor

China
Peking Union Medical College Hospital

Not yet recruiting

Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma

Biliary Tract Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma

Unrescetable Hepatocellular Carcinoma

China
WenBo Guo

Recruiting

Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy (ROSE)

Hepatocellular Carcinoma | Regorafenib | Transcatheter Arterial ChEmoembolization

China
Sun Yat-sen University

Recruiting

Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

Breast Cancer Metastatic

China
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Breast Cancer Metastatic

China
Xin-Hua Xu

Recruiting

A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma

Oral Cavity Squamous Cell Carcinoma

China
Peking University Sixth Hospital
Peking University First Hospital; Sichuan Provincial People's Hospital; Shenzhen... and other collaborators

Recruiting

Software-delivered CBT-I for Insomnia Disorder

Insomnia Disorder

China
Spanish Breast Cancer Research Group
AstraZeneca

Recruiting

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (TRANSCENDER)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain
Shanghai East Hospital

Not yet recruiting

Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial

Helicobacter Pylori Infection

China
Wu Jun

Recruiting

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Gastric Cancer

China
Cellworks Group Inc.

Recruiting

myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports (myCare-102)

Cancer | Relapsed Cancer | Refractory Cancer

United States
Universitätsklinikum Hamburg-Eppendorf
Gemeinsamer Bundesausschuss (G-BA); Staburo GmbH

Recruiting

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (AlloRelapseMM)

Multiple Myeloma

Germany
Novo Nordisk A/S

Recruiting

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels (REDEFINE 3)

Cardiovascular Disease

Netherlands, Australia, Italy, United States, Serbia, Spain, United Kingdom, Thailand, India, Malaysia, Turkey, Mexico, Canada, Argentina, Germany, France, Poland, South Africa, Brazil, Bulgaria, Colombia, Denmark, Ireland, Japan
Sun Yat-sen University

Not yet recruiting

Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy

Ovarian Cancer

China
Federation Francophone de Cancerologie Digestive

Not yet recruiting

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy (TRIPLET)

Metastatic Cancer | Metastatic Tumor | HCC - Hepatocellular Carcinoma

France
University Hopsital Schleswig Holstein Campus Lübeck

Recruiting

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients (ELIAS)

Newly Diagnosed Multiple Myeloma

Germany
West China Hospital

Recruiting

Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Non-small Cell Lung Cancer

China
Nanfang Hospital of Southern Medical University

Recruiting

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Fudan University
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Not yet recruiting

Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC)

Unresectable Hepatocellular Carcinoma
Bristol-Myers Squibb

Recruiting

A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (SWITCH - ITA)

Multiple Sclerosis, Relapsing-Remitting

Italy
Genmab
AbbVie

Recruiting

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3)

Diffuse Large B-Cell Lymphoma

France, Korea, Republic of, Spain, Belgium, Japan, Germany, Czechia, United Kingdom, Italy, Austria, United States, Poland
Shen Lin
RemeGen Co., Ltd.

Not yet recruiting

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Advanced Solid Tumor | Advanced Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma | HER2

China
Fujian Cancer Hospital

Not yet recruiting

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Rectal Cancer
Gilead Sciences
Alliance Foundation Trials, LLC.; NSABP Foundation Inc

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63) (ASCENT-05)

Triple Negative Breast Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (JANUS)

Stage III Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Locally Advanced Rectal Carcinoma

United States, Puerto Rico

3

Subscribe